Sintilimab，Surufatinib
PreclinicalSmall molecule
Sintilimab，Surufatinib is one of 44 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
96 competitors in Neuroendocrine Carcinoma
#DrugCompanyPhaseTrials
1Tarlatamab-Dznl
AmgenPhase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Inlyta
PPrism Pharmaceuticals
Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Sandostatin LAR
NovartisPhase 3
Keytruda
Merck & Co.Phase 2
Camptosar
PfizerPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Imfinzi
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sintilimab，Surufatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details